12/06/2026 Sanofi’s Tzield approved in the US for patients recently diagnosed with stage 3 T1D Sanofi’s Tzield approved in the US for patients recently diagnosed with stage 3 T1D (Ref) Sanofi announced that the US FDA had granted accelerated approval to Tzield (teplizumab-mzwv; CD30directed mAb) to delay the decline in endogenous (own) insulin production in children aged eight to 17 years recently diagnosed with stage 3 T1D. The approval was supported by the Phase 3, PROTECT/

22/04/2026 Roche announced Phase 3 data for fenebrutinib in RMS Johnson & Johnson announced Phase 3 data for nipocalimab in gMG Sanofi's Tzield approved in the US to delay the onset of stage 3 T1D in young children Roche announced Phase 3 data for fenebrutinib in RMS (Ref) Roche announced new positive data from the Phase 3 FENhance 1 and 2 studies, Which investigated fenebrutinib (BTK inhibitor) for the treatment of patients with Relapsing Multiple Sclerosis (RMS). FENhance 1